Track Cullinan Oncology, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Cullinan Oncology, Inc. CGEM · Stock Open Cullinan Oncology, Inc. in new tab

10.27 USD
EPS
-3.09
P/B
2.62
ROE
-55.54
Beta
-0.06
Target Price
34.70 USD
Loading chart...
Key Metrics
Earnings dateMarch 17, 2027
EPS-3.09
Book Value4.33
Price to Book2.62
Debt/Equity0.71
% Insiders0.425%
Estimates
Forward P/E-4.84
Forward EPS-2.34
Target Mean Price34.70

DCF valuation

Model fair value for Cullinan Oncology, Inc. (CGEM)
Result
Sign in to run the valuation for CGEM.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
10 analysts · consensus Strong buy · mean target 34.70 USD (low 27.00, high 44.00) · as of 12 Nov 2026
Low 27.00
Mean 34.70
High 44.00
Price 10.27
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Cullinan Oncology, Inc. Logo Cullinan Oncology, Inc. Analysis (CGEM)

United States Health Care Official Website Stock

Is Cullinan Oncology, Inc. a good investment? Cullinan Oncology, Inc. (CGEM) is currently trading at 10.27 USD. Market analysts have a consensus price target of 34.70 USD. This suggests a potential upside from current levels.

Earnings Schedule: Cullinan Oncology, Inc. is expected to release its next earnings report on March 17, 2027. The market consensus estimate for Forward EPS is -2.34.

Investor FAQ

Does Cullinan Oncology, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Cullinan Oncology, Inc.?

Cullinan Oncology, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 17, 2027. The company currently has a trailing EPS of -3.09.

Company Profile

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Exchange Ticker
NMS (United States) CGEM
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion